In ovarian cancer, PD-L1 expression and tumor-infiltrating lymphocytes have not consistently predicted benefit from PD-1 blockade, and single-agent PD-1 activity has been modest [10,11,31,35,45]. Here, PDCD1 is linked to neoplasm.